PULSE BIOSCIENCES INC (NASDAQ: PLSE)

PULSE BIOSCIENCES INC

NASDAQ: PLSE (Pulse Biosciences, Inc)

Last update: 23 Dec, 2025, 2:00PM

14.74

-0.46 (-3.03%)

Add to watchlist

Previous Close	15.20
Open	15.11
Volume	112,046
Avg. Volume (3M)	171,839
Market Cap	998,894,080

Price / Sales	11.29
Price / Book	10.76

52 Weeks Range	12.56 (-14%) — 25.00 (69%)
Earnings Date	5 Nov 2025

Market Trend

		Short Term	Medium Term
Industry	Medical Instruments & Supplies (US)	Bullish	Mixed
	Medical Instruments & Supplies (Global)	Bullish	Mixed
Stock	Pulse Biosciences, Inc	Mixed	Bullish

AIStockmoo Score

0.5

Analyst Consensus	2.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	0.0
Technical Oscillators	2.0
Average	0.50

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
PLSE	999 M	-	-	10.76
MMSI	5 B	-	44.30	3.14
ATRC	2 B	-	-	4.33
LMAT	2 B	0.94%	36.64	5.12
AZTA	2 B	-	63.00	1.05
STAA	1 B	-	-	2.95

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Sector	Healthcare
Industry	Medical Instruments & Supplies
Investment Style	Small Growth
% Held by Insiders	74.00%
% Held by Institutions	8.62%

Ownership

Name	Date	Shares Held
Griffin Asset Management, Inc.	30 Sep 2025	227,312

No data within this time range.

Date	Type	Details
09 Jan 2026	Announcement	Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
06 Jan 2026	Announcement	Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
29 Dec 2025	Announcement	Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
19 Dec 2025	Announcement	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Dec 2025	Announcement	Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
09 Dec 2025	Announcement	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
21 Nov 2025	Announcement	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2025	Announcement	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
05 Nov 2025	Announcement	Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
24 Oct 2025	Announcement	Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
22 Oct 2025	Announcement	Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
16 Oct 2025	Announcement	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Total Debt/Equity (MRQ)	7.24%
Current Ratio (MRQ)	15.58
Operating Cash Flow (TTM)	-40.08 M
Levered Free Cash Flow (TTM)	-19.59 M

Return on Assets (TTM)	-43.61%
Return on Equity (TTM)	-77.86%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)